Adam Brufsky
MD, PhD
Professor of Medicine
University of Pittsburgh

Adam M. Brufsky, MD, PhD, is Professor of Medicine at the University of Pittsburgh School of Medicine. He Medical Director, Women’s Cancer Center at the UPMC Magee Women’s Hospital, Pittsburgh, PA. He also serves as the Associate Director for Strategic Initiatives for the UPMC Hillman Cancer Center in Pittsburgh, PA.
Dr. Brufsky received an in Chemistry (Cum Laude) from Dartmouth College in Hanover, New Hampshire. He earned his MD and his PhD in Developmental Biology at the University of Connecticut School of Medicine in Farmington, CT. He was an Intern and Resident in Internal Medicine at Brigham and Women’s Hospital, Harvard Medical School, Boston, MA. He then completed a Fellowship in Medical Oncology and Bone Marrow Transplantation and the Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, where his appointments included Associate Physician and Instructor in Medicine at Dana Farber Cancer Institute and Harvard Medical School in Boston, MA.
Dr. Brufsky is board certified in Internal Medicine and Medical Oncology by the American Board of Internal Medicine. He is an active member of the American Society of Clinical Oncology and the American Association for Cancer Research. He has authored or co- authored more than 300 abstracts and research articles in leading journals, including the New England Journal of Medicine, Journal of Clinical Investigation, Journal of Clinical Oncology, and Lancet Oncology. Dr. Brufsky is a Principal Investigator on several research grants funded by the National Institutes of Health, Susan G. Komen Foundation, and US Army Breast Cancer Research Program.

Sessions

Register
General Session

Debate: Novel Endocrine Agents: Do PROTAC, CERAN, SERM, SERCA Really Add Anything Different than SERDs? - NO

Friday, November 01, 2024
10:50 AM - 11:05 AM
General Session

Debate: Novel Endocrine Agents: Do PROTAC, CERAN, SERM, SERCA Really Add Anything Different than SERDs? - DISCUSSION

Friday, November 01, 2024
11:05 AM - 11:15 AM
General Session

Case Discussions

Friday, November 01, 2024
11:15 AM - 11:55 AM